Brief: Lianbio Reports First Quarter 2023 Financial Results And Provides Corporate Update

LianBio

11/05/2023 22:09

Lianbio  LIAN.O :
    * REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES
CORPORATE UPDATE
    * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $286.5
MILLION WITH RUNWAY THROUGH END OF 2024
    * PHASE 3 TRIAL OF MAVACAMTEN IN CHINESE PATIENTS WITH
SYMPTOMATIC
OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) MET PRIMARY
ENDPOINT
    * CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)
ACCEPTED
MAVACAMTEN NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW
    * CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND
RESTRICTED
CASH AT MARCH 31, 2023 TOTALED $286.6 MILLION
    * SEES CURRENT CASH, CASH EQUIVALENTS, MARKETABLE
SECURITIES, &
RESTRICTED CASH SUFFICIENT TO FUND CURRENT OPERATING PLAN
THROUGH END OF 2024
    * QTRLY LOSS PER SHARE $0.22
    * Q1 EARNINGS PER SHARE VIEW $-0.27 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX6Ht7nW 
Further company coverage:  LIAN.O